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Abstract
Biological datasets amenable to applied machine
learning are more available today than ever be-
fore, yet they lack adequate representation in the
Data-for-Good community. Here we present a
work in progress case study performing analysis
on antimicrobial resistance (AMR) using stan-
dard ensemble machine learning techniques and
note the successes and pitfalls such work entails.
Broadly, applied machine learning (AML) tech-
niques are well suited to AMR, with classifica-
tion accuracies ranging from mid-90% to low-
80% depending on sample size. Additionally,
these techniques prove successful at identifying
gene regions known to be associated with the
AMR phenotype. We believe that the extensive
amount of biological data available, the plethora
of problems presented, and the global impact of
such work merits the consideration of the Data-
for-Good community.
1. Introduction
Applied data analysis has seen explosive growth in popular
interest in recent years. In parallel with this growth,
there has been an increased interest in “democratizing”
the tools and techniques for use by communities who
might not have access otherwise. In many ways the
machine learning problems faced by such communities are
identical to the needs of larger institutions (i.e. return on
investment optimization is technically similar regardless of
the tax status of the company). Yet, significant shortage
of skilled workers has created salary requirements that
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prevent nonprofits from competing. This reflects a broader
trend in the nonprofit sector struggling to find IT talent.
Exacerbating this problem are the struggles associated
with trying to integrate a machine learning expert/team
into an existing business structure or software stack. To
counteract this trend organizations for several years have
made great strides both in training new individuals perform
data analysis and encouraging advanced practitioners (e.g.
PhD graduates in Computer Science or Statistics) to pursue
this work. The Data-for-Good community (such as Data
Science for Social Good fellowship and the IBM Social
Good Fellowship) has achieved remarkable success in
promoting work directly with not-for-profit organizations,
non-government organizations, or local governments. Here
we are encouraging machine learning practitioners to con-
sider the analysis of public biological datasets with a focus
on problems that would have the greatest value to medical
facilities in underserved communities. Using our work
on genotype to phenotype classification of AMR as a
case study, we note how AML techniques can yield real
advances in the field. Biology and medicine are rich with
a multitude of problems, many of which are very niche
big business investments. We hope to attract the attention
of the Data-for-Good community to this class of problems
which we believe will be an area of growth, both in and
out of the Data-for-Good community, over the next decade.
Here we present work in progress, which was originally
intended to demonstrate to biologists the power AML
can have on many problems they are interested in. We
believe it also serves as a good case study for the Data-for-
Good movement: our use of off-the-shelf classifiers applied
to public datasets to answer unique real-world problems
shares a great similarity with the type of problems the Data-
for-Good community attempts to solve.
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2. Background
The very foundation of computational biology rests on the
application of computer science to biological problems.
Similarly, the biostatistics community has a long history
of investigating the unique statistical problems that biology
presents. Well-funded Silicon Valley startups, such as
23andMe, are in the business of collecting large amounts of
data and applying statistical techniques typical of applied
machine learning or “big data” analysis. Meanwhile, Deep
Genomics targets particularly tricky biological problems
with both copious data and advanced deep learning tech-
niques. Historically, advances in computational biology
have been achieved with well targeted small datasets or
datasets which are hard to generate. In contrast, current
growth in the field is typified by large scale aggregation
of data using various protocols, standards and databases.
We believe this aggregation of large datasets will create a
unique opportunities for a variety AML solutions and most
importantly increased involvement of practitioners.
2.1. Data-for-Good Aspects of AMR
AMR is a well recognized problem with profound impli-
cations for global health (CDC, US; Organization et al.,
2014; House, 2015). In many biological disciplines grant
application guidelines or funding agencies typically require
that the data generated and used for analysis in the course
of a study are made publicly available. This allows unique
opportunity for large-scale aggregation platforms, such
as Pathosystems Resource Integration Center (PATRIC)
(Gillespie et al., 2011) to serve a unique role. These
platforms provide greater access to data but are currently
geared toward professional biologists. Some of their
pros/cons are:
Advantages
• Global impact
• Rich datasets
• Ample availability of access
• Presents applied and theoretical problems
Disadvantages
• Minimal documentation
• Experts required
• Easy to misinterpret
• Unclear how to operationalize analytical results
We note that the principal disadvantages listed above are
mainly related to putting the data into a format that is easily
accesible to an AML professional, rather than a profes-
sional biologist. We note that these problems are not unique
to computational biology and have been surmounted in
other domains either through standardization of the data
processing or attachment of metadata.
Figure 1. Occurrence of unique k-mers in the MTB strain
1773.372. y-axis shows how many times a k-mer count (x-axis)
appeared.
Figure 2. Adabost performed on MTB strain Rifampicin resistant
3. AMR Case Study
Identification of regions and genes associated with antimi-
crobial resistance is an extensively studied topic. While
we have analysed a variety of datasets (Table 2), here we
focus on principally three different species of bacteria–
Streptococcus pneumoniae (β-lactams resistant), Acineto-
bacter baumannii (carbapenems resistant) and Mycobac-
terium tuberculosis (isoniazid resistant) (Chewapreecha
et al., 2014).
3.1. Analysis
The Random Forest (RF) analysis (Breiman, 2001)
was performed using the default settings of the
scikit-learn API (Pedregosa et al., 2011). Other
algorithms (e.g. Adaboost (Freund & Schapire, 1997),
logistic regression and deep learning among others) were
investigated, however these results are largely beyond the
scope of this paper. All analysis was performed using
Python 2.7 on a 32 core machine with 1TB RAM.67
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Table 1. A comparison of the relationship between choice of k-
mer length, the total number of unique k-mers, and the size of the
dataset on disk.
k k-MERS COUNTS SIZE
10 518304 214MB
11 1,857,213 733MB
12 5,058,522 2.0GB
13 9,502,404 3.7GB
14 13,171,189 5.1GB
15 15,258,381 6.0GB
20 17.653,652 7.0GB
25 18,816,555 7.5GB
30 19,882,628 8.0GB
Table 2. Sample set of currently available datasets on the
Pathosystems Resource Integration Center (PATRIC) system.
SUS and RES designate susceptible and resistant strains,
respectively.
STRAIN NAME ANTIBIOTIC SUS RES
A. baumannii CARBAPENEM 110 122
M. tuberculosis ETHAMBUTOL 878 464
M. tuberculosis ETHIONAMIDE 283 174
M. tuberculosis ISONIAZID 580 986
M. tuberculosis KANAMYCIN 504 202
M. tuberculosis MOXIFLOXACIN 277 103
M. tuberculosis OFLOXACIN 492 267
M. tuberculosis RIFAMPICIN 545 715
M. tuberculosis STREPTOMYCIN 883 571
S. aureus METHICILLIN 115 491
S. pneumoniae BETA-LACTAM 1505 1563
S. pneumoniae TRIMOXAZOLE 585 2126
Figure 3. ROC plots for RF and Lasso. RF is trained on 100 trees.
3.2. Data Preprocessing
Assembled DNA contigs (partially assembled medium
length strands of DNA that represent each isolate) were
converted to k-mers (fixed length short strands typically
of length of 10 − 50). Each isolate is represented by its
unique k-mer count as features. Table 1 shows how the
choice of k effects k-mer count and final dataset size. We
have two variables we can tune–the first is the size of k, the
second is the number of isolates to consider. Setting k = 1
is equivalent to finding the cellular GC-content (i.e. the
percent of guanine (G) or cytosine (C) nitrogenous bases
on the DNA molecule), which is used for coarse-grained
analysis in computational biology. We note that overall
size of the dataset matrix expands rapidly at roughly
around k = 13 (Figure 1). In addition, as demonstrated in
Figure 2, a larger k yields a better ROC metric. Conversely,
on another dataset (Figure 3) we note that both RF and
Lasso perform fairly similarly regardless of the size of
k. We believe further investigation of the generalizability
across species and phenotypes is necessary and have noted
when our analysis included k-mers of different lengths.
Figure 4. A list of the top gene regions, by PATRIC ID, identified
from feature importance calculated using RF on decreasing
sample sizes of MTB. Note that ultimately the top gene region
places in top 5 with as little as 25 samples.
3.3. Overview of Results
RF performs remarkably well in general. We predict
AMR phenotypes using an 80/20 train/test split, obtaining
accuracies as high as 92%. Figure 5 shows that the
accuracies of the algorithm decrease as a function of
the number of isolates trained on, while Figure 6 shows
that ultimately the accuracy plateaus on larger sample
sizes. Despite lower accuracies, Figure 4 shows that the
top ranked gene regions show stability even at a lower
accuracy. Smaller datasets may show accuracies that
are concerning, yet they may still be accurate enough to
identify key locations of mutations that confer phenotype.
Further tuning of the algorithm, preprocessing the data
or feature selection would increase accuracy but would
distract from our central thesis, which is chiefly that AML
techniques can rapidly be applied to open and real world
biological problems.
3.4. Discussion
We have transformed the problem of genotype to pheno-
type classification into a supervised machine learning task
in order to exploit numerous algorithms and techniques
available for classification. We believe the above demon-
strates that the performance of AML techniques can be
suitably used to investigate biological functions involved
in AMR and present some opportunities for such analysis
68
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β-lactam resistant S. pneumoniae
Carbapenem resistant A. baumannii
Isoniazid resistant M. tuberculosis
Figure 5. Average accuracy of RF on subsets of isolates of
increasing subset size. k = 10.
Figure 6. Accuracy of Random Forest averaged over various
sample sizes. k = 10.
below. These corespond to differing objectives which we
list below:
Objective I, Maximize classification accuracy: Maxi-
mizing classification accuracy is incredibly important for
long-term deep investigations of genotypic changes in
relationship to phenotype. This approach offers great value
when considering stable mutations and would allow for
the identification of a genotypic fingerprint (i.e a unique
genetic string indicative of a phenotype) of a single type
of AMR. This insight could be used for construction of a
biological assay (a devices that provides rapid diagnosis in
the field). A large collection of genetically similar isolates
undergoing a similar mutation conferring resistance would
be required, but a nuanced understanding of what defines
resistance would be achieved. This approach is perhaps
most similar to the ”leaderboard” competitions for AML.
Example use: design of an extremely accurate test for wide
spread genetically similar outbreaks.
Objective II, Maximize generalization accuracy: Gen-
eralization of classifiers for AMR phenotypes can be man-
aged across different bacteria for the same antibiotic or
across antibiotics for the same bacteria. It is known that
antibiotics affect common genes and gene functions in
bacteria, yet little is known about the generalization of the
AMR genotype across different bacteria. Example use:
designing a general purpose screening for AMR genotypes
in environmental samples or designing an algorithmic tool
for prioritizing first-line antibiotics in a new outbreak.
Objective III, Aggregate feature selection: Feature se-
lection provides crucial insight into biological processes
that confer AMR. The most productive way to cluster
features remains an open problem and one that could yield
important insight for biologists. In our representation of the
problem features are highly redundant and collapsing these
redundant features into meaningful clusters, or blocks,
provides powerful indication of the region of mutation that
confers AMR. Example use: a small fast moving outbreak
requires a corse analysis to identify regions of mutation in
order to choose an appropriate antibiotic.
4. Conclusion
We are far from the first to identify computational biology
as a productive area of research for AML researchers.
There is a concerted effort in the biostatistical community
to perform outreach towards biologists. While the separa-
tion in data analysis skills and domain knowlege between a
typical biologists and a typical statistician is very wide, we
believe the AML community and in particular the Data-for-
Good community have both the technical and dispositional
skills to manage such a divide. Furthermore, we believe
that the influx of aggregated datasets will provide both
opportunity and need for such professionals.
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